Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special PopulationsRelease Date:Research Inflammation & Immunology China Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) PathogensRelease Date:Research Inflammation & Immunology China Global Request for Proposals – Pfizer Clostridioides difficile (C. difficile) Research CollaborationRelease Date:Call for Collaborator(s) Vaccines France, Germany Initiatives to Improve the Clinical Environment for Dermatologic Immunology, Inflammation, and Allergy CareRelease Date:Partner: The Japanese Society for Cutaneous Immunology and AllergyQuality Improvement Inflammation & Immunology Japan Real World, Long-term Efficacy Study of Ritlecitinib in Adult and Adolescent Patients with Severe Alopecia Areata in ChinaRelease Date:Research Inflammation & Immunology China Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UKRelease Date:Research Internal Medicine United Kingdom Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)Education Oncology All Quality Improvement Solutions for the Diagnosis and Management of Migraine and Headache DisordersQuality Improvement Internal Medicine Canada, USA Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease China Title Grant Type Focus Area Country Application Due Date Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease USA Hereditary Transthyretin Amyloidosis Research in ChinaRelease Date:Research Rare Disease China Advances in Immuno-Oncology Therapy in Urothelial CancerRelease Date:Education Oncology Japan RWD in the management of MDR BacteRial severe InfEctions and invasive Fungal disease, ITalian experiencesRelease Date:Research Hospital Italy Quantifying the Socio-Economic Burden of Disease for Dermatology Patients and CaregiversRelease Date:Research Inflammation & Immunology Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia (Slovak Republic), Spain, Sweden, Switzerland, Turkey, United Kingdom Improving Treatment Environment for Acute LeukemiaRelease Date:Education Oncology Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) ResearchRelease Date:Research Rare Disease USA Transthyretin Cardiac Amyloidosis Fellowship - United StatesRelease Date:Fellowship Rare Disease USA Applying Patient-Reported Outcomes in Oncology Patient Care Using Quality Improvement and Implementation Science StrategiesQuality Improvement Oncology USA Understanding and Mitigating Cardiovascular Risk in Patients with Prostate CancerQuality Improvement Oncology USA Cardiac Amyloidosis Mentor mATTch pRogramEducation Rare Disease USA Knowledge Gaps in Testing, Diagnosis and Treatment of COVID-19Release Date:Education Hospital USA